Last year, chemist Marcus Tius at the University of Hawaii saw a paper describing the synthesis of some organic compounds, and was “struck by the implausibility” of the reported structures. So he joined up with some colleagues to try to replicate the data.
While Tius and his team were trying to repeat the experiment, however, in December 2017 the journal — Organic Letters — retracted the paper. The journal, published by the American Chemical Society, noted that the authors had not been able to produce crystal structures that confirm they had synthesized those compounds in particular. So Tius and his colleagues knew they couldn’t replicate the findings — but carried on their experiment anyway:
What Caught Our Attention: In the span of 48 hours, PLOS ONE retracted two papers this month that were co-authored by Bo Yu, based at Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment and The Second Affiliated Hospital of Harbin Medical University in China. Both notices cite multiple duplications and errors, and conclude:
A pharmacy journal has retracted a 2017 cancer paper after determining that the lead author forged her co-author’s signature.
Alain Li Wan Po, editor-in-chief of the Journal of Clinical Pharmacy and Therapeutics, told Retraction Watch that, after discovering the forgery,the journal lost confidence in “the integrity of the whole report,” and decided to retract it:
Our judgment was that if an author is willing to forge a signature, we cannot be sure of the integrity of the whole report and decided on the retraction.
According to Po, the paper’s lead author, Yan Wang, objected to the retraction because “she maintained that the data were accurate.” So the editors retracted the paper without her approval — but with the agreement of the author Jatinder Lamba, whose name was forged.
How did the journal discover the forged signature?